drugset / Trial / NCT00716859
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
Timeline
- Start
- 2008-07
- Primary completion
- 2009-11
- Completion
- 2009-11
Outcome
Missed primary endpoint
registry analysis (unspecified test); Timolol vs Latanoprost; Mean Difference (Net) 1.46 (95% CI -0.81 to 3.74) NCT00716859 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latanoprost | Small molecule | 0.005 % | — |
| Comparator | Timolol | Other / unclassified | 0.5 % | — |